Earnings date set: Hims & Hers will release Q1 2026 results on May 11, with consensus revenue near $616M and EPS at $0.13. Novo Nordisk pact: A March settlement allows sales of brand-name GLP-1 drugs, ...
Healthcare stocks have struggled in 2026. With a year-to-date (YTD) loss of about 6%, that corner of the market has been the ...
Novo Nordisk A/S expects generic Ozempic to be delayed in China until next year, a positive step for the drugmaker as it ...
JPMorgan initiated Hims & Hers (HIMS) with Overweight and $35 target, citing Novo Nordisk (NVO) partnership as a turning point legitimizing the GLP-1 business. JPMorgan’s endorsement reframes Hims & ...
Hims & Hers Health (NYSE:HIMS) just picked up a high-profile endorsement. JPMorgan analyst Cory Carpenter initiated coverage with an Overweight rating and a $35 price target, framing the telehealth ...
Novo Nordisk will seek regulatory approval for its semaglutide pill to treat Type 2 diabetes in children and adolescents after a late-stage trial showed it significantly reduced blood sugar in 10- to ...
Him & Hers announced Thursday that eligible users can now access the full range of U.S. Food and Drug Administration (FDA)-approved GLP-1 medications on its platform. Providers can now send ...
April 22 (Reuters) - Telehealth company Hims & Hers (HIMS.N), opens new tab said on Wednesday it has a steady supply of estrogen patches and is offering them to patients through its platform, as ...
Hims & Hers (HIMS) stock surged as much as 49% in five trading sessions, with an 11% gain on Monday alone. The FDA announced a July meeting to consider easing restrictions on 12 peptides, opening a ...
Hims & Hers (HIMS) shares surged on FDA peptide tailwinds and a Novo Nordisk partnership to distribute branded Wegovy, giving the company leverage in the GLP-1 market beyond compounded alternatives.
Few telehealth stocks have generated as much momentum in a single week as Hims & Hers Health has managed to pull off recently. Shares of the company, publicly traded on the New York Stock Exchange ...